People · Operator
Named in public records as an officer, director or promoter · active 2006–2024 · Biotechnology, Pharmaceuticals, Other Technology, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allakos Inc. | — | Biotechnology | Series D+ | $128.1M | $4.1B | 2012 |
| Reunion Neuroscience, Inc. | — | Pharmaceuticals | Series D+ | $119.8M | $1.5B | 2024 |
| SARcode Corp | — | Biotechnology | Series C | $99.6M | $1.8B | 2006 |
| Sonexa Therapeutics Inc | — | Pharmaceuticals | Series B | $41.5M | $68.0M | 2008 |
| Kizzang Llc | — | Other Technology | Pre-Seed | $770K | $32.6M | 2013 |
| Auralab Technologies Inc | — | Software / Tech | Pre-Seed | $425K | $10.6M | 2021 |
Robert Alexander at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Alexander on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dan Janney | 2 | 4 |
| Briggs Morrison | 1 | 8 |
| Louis C. Bock | 1 | 7 |
| Ansbert Gadicke | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| John McKearn | 1 | 6 |
| Michael Ehlers | 1 | 6 |
| Peter Moldt | 1 | 6 |
| DENNIS HENNER | 1 | 5 |
| Edward Smith | 1 | 5 |
| Farah Champsi | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| Paul Walker | 1 | 4 |
| Emmett Cunningham | 1 | 4 |
| Nathan Bryson | 1 | 3 |
| Thomas Gadek | 1 | 3 |
| Mark Theeuwes | 1 | 3 |
| Quinton Oswald | 1 | 3 |
| Ellen Lubman | 1 | 2 |
| Nenad Tomasevic | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.